Advanced Biomed Inc.
ADVB Nasdaq· Services-Medical Laboratories
Last close · Oct 23, 2026
$3.17
KIRA · Stoqly’s AI analyst, in plain words
- Advanced Biomed Inc. had $0.1M of revenue in fiscal 2026.
- Its operating margin was −4,885.2%: of every 100 in sales, about −4,885 is left after running the business.
- Advanced Biomed Inc. made $6.7M of net profit in fiscal 2026.
Market cap
$4.0M
P/E
0.6x
Revenue
$0.1M
Net income
$6.7M
Free cash flow
—
Operating margin
−4,885.2%
Advanced Biomed Inc. in 30 seconds · fiscal 2026
Does it make a profit?
5,232.8%
Yes. It keeps 5,232.8% of every sale as profit.
How is the share priced?
0.6x
One share costs 0.6 times its yearly profit per share.
What Advanced Biomed Inc. does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Oct 13, 2026
- Legal name
- Advanced Biomed Inc.
- CIK
- 0001941029
Advanced Biomed Inc. · ADVB
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 | FY26 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | — | — | $0.1M |
| Operating margin | — | — | −4,885.2% |
| Net income | −$2.8M | −$3.3M | $6.7M |
| Net margin | — | — | 5,232.8% |
| Diluted EPS | −$0.14 | −$3.18 | $5.33 |
| Cash | |||
| Cash from operations | −$2.1M | −$5.8M | −$1.9M |
| Capital expenditure | $0.1M | $0.0M | — |
| Free cash flow | −$2.2M | −$5.9M | — |
| Share count change | — | −94.9% | 22.1% |
| Debt and strength | |||
| Cash and short-term investments | $2.6M | $0.0M | $0.4M |
| Shareholders' equity | $1.7M | $3.5M | $12.3M |
| Current ratio | 1.1x | 1.2x | 9.3x |
| Returns and quality | |||
| Return on equity | −167.3% | −126.8% | 84.8% |
| Return on tangible equity | −180.2% | −93.7% | 54.4% |
| Altman Z'' | — | −2.0 | 8.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Advanced Biomed Inc. · ADVB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.17 a share, the company is worth $4.0M: 0.6 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001941029). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.